stockrowRevolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
Revolution Medicines, Inc. (RVMD) Total debt
Revolution Medicines, Inc.'s total debt at the end of fiscal 2025 was $268.4M, up 367.4% from $57.4M in fiscal 2022. At the end of the quarter to 30 June 2026 it was $1.0B. Over the past ten years it has ranged from $147.0K (fiscal 2018) to $268.4M (fiscal 2025) — the current reading is the highest in ten years. Revolution Medicines, Inc. ranks 12th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $268.4M | 367.42% |
| FY2022 | $57.4M | (4.94%) |
| FY2021 | $60.4M | 108.40% |
| FY2020 | $29.0M | 16,755.81% |
| FY2019 | $172.0K | 17.01% |
| FY2018 | $147.0K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $1.0B | 269.14% |
| Mar 2026 | $280.6M | 4.54% |
| Dec 2025 | $268.4M | 4.65% |
| Sep 2025 | $256.5M | 4.66% |
| 17 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| RPRX Royalty Pharma PLC compare | $8.6B |
| GMAB Genmab A/S Sponsored ADR compare | $5.1B |
| RVMD Revolution Medicines, Inc. | $1.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $825.2M |
| INSM Insmed, Inc. compare | $562.8M |
| BNTX BioNTech SE Sponsored ADR compare | $414.1M |
| ROIV Roivant Sciences Ltd. compare | $323.7M |
| INCY Incyte Corporation compare | $27.6M |
| ARGX argenex SE compare | $7.6M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on RVMD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement